The publisher explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29.
Snapshot
Model updates (22 July 2020)
Model updates (22 April 2020)
Model updates (30 January 2020)
Model updates (28 October 2019)
Model updates (23 July 2019)
Snapshot
- Overview: Biogen’s prescription pharmaceutical business will see stable performance over the medium term.
- Key themes: [1] Biogen’s flagship MS portfolio – Tecfidera, Avonex, Plegridy, and Tysabri – remains incredibly stable [2] Spinraza revenues will plateau during the forecast period due to competition from newer products [3] Biogen’s revival of aducanumab is a surprise and will add significant revenue during the forecast period.
Model updates (22 July 2020)
- Tecfidera forecast adjusted significantly lower due to litigation outcome resulting in earlier generic competition
- Vumerity forecast adjusted lower due to later expected launch in EU and RoW
- Imraldi forecast adjusted lower in EU.
Model updates (22 April 2020)
- Vumerity forecast adjusted lower due to continued slow launch.
Model updates (30 January 2020)
- Spinraza forecast adjusted higher due to continued international growth
- Avonex forecast adjusted lower due to continued competition in multiple sclerosis
- Vumerity forecast adjusted lower due to initial launch trends.
Model updates (28 October 2019)
- Spinraza forecast adjusted lower in the US
- Imraldi forecast adjusted higher due to quicker adoption
- Ocrevus royalty forecast adjusted higher due to continued ramp of Ocrevus in all types of MS
- Aducanumab forecast added.
Model updates (23 July 2019)
- Tecfidera sales adjusted lower in 2028 due to patent expiration
- Tysabri sales adjusted higher due to less impact from competition
- Spinraza sales adjusted lower due to pending competition from Zolgensma and risdiplam
- Benepali sales adjusted lower due to stabilization in five major EU markets and RoW
- Rituxan/Gazyva royalties adjusted higher due to lower than expected biosimilar impact
- Ocrevus royalties adjusted higher due to strong momentum in the US and other global approvals
- Vumerity launch delayed to 2020 in the US
- Aducanumab removed from forecast after failing Phase III ENGAGE and EMERGE trials
- BIIB067 forecast added.
Table of Contents
Company Background- Company Overview
- Key Metrics
- SWOT Analysis
- Key Drug & Company Information
- Company Comparison
Recent Earnings Review
- Earnings Overview
- Notable Quotes & Important Topics
- Pharma Insights Analysis
Company Forecast
- Prescription Pharmaceuticals Sales Outlook
- Branded Drug Outlook
- Launch Profile Outlook
- Therapy Area Outlook
- Regional Sales Outlook
- Lifecycle Analysis
Company Profile
- Marketed & Pipeline Drugs
- Recent Events & Analyst Opinions
- Upcoming Catalysts
- Recent Insights
Clinical Trial Overview
- Clinical Trial Snapshot
- Clinical Trials by Country
- Clinical Trials by Status and Phase
- Clinical Trials by Drug
